Opportunities in traditional pharma companies with a focus on domestic formulations and US generics are drying up because of a slowdown in new approvals and regulatory issues.

Despite muted returns in broader markets, India’s IPO space has outperformed in 2025, with 27 of 30 listings trading above ...

Anthem Biosciences Limited has made an initial public offering of equity shares aggregating to ₹3,395 crore. Trilegal represented Anthem Biosciences along with ...

Anthem Biosciences had a robust launch on the stock exchanges today. On the NSE, the stock began trading at ₹723.05 each, ...

The Bengaluru-based contract research, development, and manufacturing organisation (CRDMO) saw overwhelming investor demand, with the Rs 3,395-crore IPO getting subscribed 67.42 times overall.

AM, Anthem Biosciences share price on the BSE was trading at Rs. 730.70, up Rs. 7.60 or 1.05% from the listing price and a 28.19% gain over the issue price. On the NSE, the stock was quoted at Rs. 730 ...

Anthem Biosciences Ltd ended its debut trading day with a premium of over 28%. Despite the high opening figures, the company ...

Anthem Biosciences IPO listing date is today. Ahead of the listing, Anthem Biosciences IPO GMP today and analysts signal a ...

True North and Faering-backed Anthem Biosciences surges ~28% on NSE/BSE debut, reflecting strong IPO sentiment and investor ...

Anthem Biosciences shares experienced a surge after a strong stock market debut, exceeding its IPO price by 27%. Investors ...

Its shares were listed at Rs 723 apiece on the BSE, a premium of 26.85 per cent as against the IPO issue price of Rs 570.

Anthem Biosciences, a leading contract research and manufacturing organization (CRDMO), made a strong debut on the Indian ...